ECONOMIC ANALYSES OF TRASTUZUMAB BIOSIMILAR FOR TREATMENT OF PATIENTS WITH HER2-POSITIVE BREAST CANCER FROM A BRAZILIAN PRIVATE HEALTHCARE PERSPECTIVE

被引：0
|
作者：
Tanaka, S. [1 ]
Suri, G. [2 ]
Despiegel, N. [3 ]
Nascimendo, C. [1 ]
Aratangy, G. [1 ]
机构：
[1] Amgen Inc, Sao Paulo, Brazil
[2] Amgen Inc, London, England
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN147
引用
收藏
页码：S449 / S449
页数：1
相关论文
共 50 条
  • [41] Beyond trastuzumab: New treatment options for HER2-positive breast cancer
    Saini, Kamal S.
    Azim, Hatem A., Jr.
    Metzger-Filho, Otto
    Loi, Sherene
    Sotiriou, Christos
    de Azambuja, Evandro
    Piccart, Martine
    BREAST, 2011, 20 : S20 - S27
  • [42] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
    Paridaens, R., Sr.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Cadic, V.
    Pinel, M.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [44] Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer
    Morris, Shannon R.
    Carey, Lisa A.
    ONCOLOGY-NEW YORK, 2006, 20 (14): : 1763 - 1771
  • [45] Infusion Reactions in HER2-Positive Gastric Cancer: Switching from Trastuzumab to Its Biosimilar
    Abe, Tomoya
    Sagara, Atsunobu
    Suzuki, Takayuki
    Okada, Daichi
    Matsuzaka, Kazumasa
    Nakayama, Toshiaki
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2024, 47 (08) : 1452 - 1455
  • [46] An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
    Chen, Wen
    Jiang, Zefei
    Shao, Zhimin
    Sun, Qiang
    Shen, Kunwei
    VALUE IN HEALTH, 2009, 12 : S82 - S84
  • [47] Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
    Untch, Michael
    Rezai, Mahdi
    Loibl, Sibylle
    Fasching, Peter A.
    Huober, Jens
    Tesch, Hans
    Bauerfeind, Ingo
    Hilfrich, Joern
    Eidtmann, Holger
    Gerber, Bernd
    Hanusch, Claus
    Kuehn, Thorsten
    du Bois, Andreas
    Blohmer, Jens-Uwe
    Thomssen, Christoph
    Costa, Serban Dan
    Jackisch, Christian
    Kaufmann, Manfred
    Mehta, Keyur
    von Minckwitz, Gunter
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2024 - 2031
  • [48] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Yamshiro, Hiroyasu
    Iwata, Hiroji
    Masuda, Norikazu
    Yamamoto, Naohito
    Nishimura, Reiki
    Ohtani, Shoichiro
    Sato, Nobuki
    Takahashi, Masato
    Kamio, Takako
    Yamazaki, Kosuke
    Saito, Tsuyoshi
    Kato, Makoto
    Lee, Tecchuu
    Ohno, Shinji
    Kuroi, Katsumasa
    Takano, Toshimi
    Takada, Masahiro
    Yasuno, Shinji
    Morita, Satoshi
    Toi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 709 - 722
  • [49] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 709 - 722
  • [50] Trastuzumab improves survival, outcomes of HER2-positive breast cancer patients
    不详
    FORMULARY, 2006, 41 (03) : 146 - +
12345